Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
BioCentury This Week
00:00
Introduction
This week pod a landlark approval in imuno oncology. And we dust the tool box for alternative financings. The sponsor for this episode of bia century is jto capital.
Play episode from 00:00
Transcript
